Rgenta Therapeutics Inc.

https://www.rgentatx.com

LinkedIn: https://linkedin.com/company/rgenta-therapeutics-inc

Rgenta Therapeutics is developing a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology and neurological disorders. Our proprietary platform mines the massive genomics data to identify targetable RNA processing events and design small-molecule glues to modulate the interactions among the spliceosome, regulatory proteins, and RNAs. Our lead programs and unique approach are unlocking the therapeutic potential of historically undruggable targets in human diseases. *

	Start	2019-01-01 established (s-off)
	Predecessor	University of Massachusetts Medical School (UMASS Medical School)
	Industry	RNA-targeting small molecule drugs (rSMs)
	Industry 2	drug development
	Person	Xi, Hualin (Simon) (Rgenta Therapeutics 202004 CEO + CO-Founder)
	Person 2	Heidecker, Martin (AMR Action Fund 202301 Chief Investment Officer before Boehringer Ingelheim Venture Fund)

	Region	Cambridge, MA
	Country	United States (USA)
	Street	700 Main Street LabCentral
	City	02139 Cambridge, MA
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«: Rgenta Therapeutics, Inc.. (4/2/20). "Press Release: Rgenta Therapeutics Launches with $20 Million Seed Investment". Cambridge, MA.

		Record changed: 2023-07-10